Oruka Therapeutics

Oruka Therapeutics

Yahoo Finance • last month

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 mill... Full story

Yahoo Finance • last month

Leerink Partners Lifts PT on Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the best performing healthcare stocks so far in 2026. Leerink Partners lifted the price target on Oruka Therapeutics, Inc. (NASDAQ:ORKA) to $120 from $109 on April 30, reaffirming an Outperf... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics (ORKA) Reports Positive Phase 2a Results for Psoriasis Treatment ORKA-001

Oruka Therapeutics (NASDAQ:ORKA) is one of the small-cap stocks that are on fire right now. On April 27, Oruka Therapeutics announced positive interim results from its EVERLAST-A Phase 2a trial for ORKA-001, a long-acting monoclonal antibo... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics prices upsized $700M public offering at $72.50 per share

Oruka Therapeutics (ORKA [https://seekingalpha.com/symbol/ORKA]) has announced an upsized public offering [https://seekingalpha.com/pr/20491699-oruka-therapeutics-announces-pricing-of-upsized-700-million-underwritten-public-offering] of 9.... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics Prices Upsized $700 Mln Offering To Advance Psoriasis Pipeline

(RTTNews) - Oruka Therapeutics, Inc. (ORKA), has priced an upsized $700.4 million underwritten public offering, strengthening its balance sheet as the company advances two late-stage dermatology programs designed for ultra-infrequent dosin... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics Announces Pricing of Upsized $700 Million Underwritten Public Offering

MENLO PARK, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and other inflammatory... Full story

Yahoo Finance • 2 months ago

Tech Earnings Optimism Powers Stocks Higher

The S&P 500 Index ($SPX) (SPY) on Monday closed up +0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +0.01%.  June E-mini S&P futures (ESM26) rose +0.14%, and June E... Full story

Yahoo Finance • 2 months ago

Stocks Slip as Higher Oil Prices Spur Inflation Concerns

The S&P 500 Index ($SPX) (SPY) today is down -0.12%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.14%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.30%.  June E-mini S&P futures (ESM26) are down -0.14%, and June E-mini Na... Full story

Yahoo Finance • 2 months ago

Stocks Pressured by Higher Oil Prices

The S&P 500 Index ($SPX) (SPY) today is unchanged, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.09%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.10%.  June E-mini S&P futures (ESM26) are down -0.02%, and June E-mini Nasdaq... Full story

Yahoo Finance • 2 months ago

How A Small Biotech Name Just Rattled AbbVie's $18 Billion Franchise

Nearly two-thirds of patients who received Oruka Therapeutics' experimental psoriasis treatment had completely clear skin after 16 weeks. Continue Reading... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin... Full story

Yahoo Finance • 2 months ago

Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on

[Heart Health Concept] Eoneren/E+ via Getty Images As the market moves into the second week of Q1 earnings, we look at the most overbought stocks in the healthcare sector. Below is a list of the top 10 healthcare stocks ranked based on t... Full story

Yahoo Finance • 2 months ago

Oruka Therapeutics price target raised to $85 from $45 at Wedbush

Wedbush raised the firm’s price target on Oruka Therapeutics (ORKA) to $85 from $45 and keeps an Outperform rating on the shares. The firm reviewed anticipated benchmarks and stock setup for upcoming induction data from the Phase 2a EVERLA... Full story

Yahoo Finance • 3 months ago

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools

Key Points VR Adviser, LLC added 1,000,000 shares of Spyre Therapeutics; estimated trade size is $25.78 million (based on quarterly average pricing). The quarter-end value of the position increased by $75.73 million, reflecting both tradi... Full story

Yahoo Finance • 3 months ago

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down

On February 17, 2026, VR Adviser, LLC disclosed in a U.S. Securities and Exchange Commission filing that it sold 5,845,915 shares of Ocular Therapeutix(NASDAQ:OCUL), an estimated $71.01 million trade based on quarterly average pricing. VR... Full story

Yahoo Finance • 3 months ago

VR Adviser Adds Over 1 Million Savara Shares

According to a filing with the Securities and Exchange Commission dated Feb. 17, VR Adviser, LLC increased its position in Savara(NASDAQ:SVRA) by 1,059,332 shares during the fourth quarter. The fund’s Savara stake ended the quarter valued... Full story

Yahoo Finance • 6 months ago

Wednesday's ETF Movers: XBI, SLVR

In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Oruka Therapeutics, up about 5.5% and shares of Arcutis Biothera... Full story

Yahoo Finance • 7 months ago

Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past three key readouts: ORKA-001 Phase 2a and 2... Full story

Yahoo Finance • 8 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin... Full story

Yahoo Finance • 8 months ago

Barclays initiates coverage on U.S. small & mid-cap biotech stocks

Investing.com -- Momentum in small and mid-cap (SMID) biotechnology has accelerated recently, with investors rewarding companies bringing new mechanisms and dosing advantages to market. Over the past six months, the Nasdaq Biotechnology I... Full story